Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Journal of Hepatocellular Carcinoma|August 19, 2021
Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and CirrhosisShimaa Kilany, Lmyaa Ata, Asmaa Gomaa, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 9, 2023
Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa regionImam Waked, Sherif Alsammany, Sayed Hammad Tirmazy, et al.
Pharmaceuticals (Basel, Switzerland)|January 28, 2026
Pharmacogenomics of Sorafenib in Hepatocellular Carcinoma (HCC): A LncRNA-Expression Guided Approach Using UCA1 and MALAT1 for Personalizing Therapy in a 154-Patient CohortMahmoud Nazih, Imam Waked, Shimaa Abdelsattar, et al.
Alimentary Pharmacology & Therapeutics|September 23, 2024
Individualized HCC surveillance using risk stratification scores in advanced fibrosis and cirrhotic HCV patients who achieved SVR: Prospective studyGamal Shiha, Ayman Hassan, Nasser Mousa, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 11, 2022
Optimized Systematic Review Tool: Application to Candidate Biomarkers for the Diagnosis of Hepatocellular CarcinomaMei Ran Abellona U, Eric Yi-Liang Shen, Caroline Cartlidge, et al.
Expert Review of Anti-Infective Therapy|July 13, 2021
Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinomaTamer Elbaz, Imam Waked, Wafaa El-Akel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 20, 2021
Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income CountriesCaroline E Boeke, Lindsey Hiebert, Imam Waked, et al.
Journal of Medical Virology|June 15, 2018
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II studyImam Waked, Gamal Esmat, Rabab Fouad, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|December 27, 2011
Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centreSayed Abdelwahab, Eman Rewisha, Mohamed Hashem, et al.
Pageof 11